A PYMNTS Company

UK Regulator Probes Elanco Asset Sale To Dechra

By  |  April 20, 2020

The UK’s Competition and Markets Authority (CMA) announced on Monday, April 20, that it is opening a formal phase 1 investigation into Elanco Animal Health’s anticipated sale of its Osurnia product portfolio to Dechra Pharmaceuticals.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The antitrust regulator stated it has a deadline of June 17 for a decision on the initial probe. Last month, the CMA announced it was considering whether the deal might be expected to hurt competition in the UK and opened a consultation which closed on April 17.

    Animal-health company Elanco in January agreed to sell Osurnia, a treatment for otitis externa in dogs, to UK veterinary medicines company Dechra for US$135 million in cash. The deal was part of Elanco’s efforts to gain regulatory clearance for its US$7.6 billion acquisition of Bayer AG’s animal-health business.

    Full Content: Market Watch

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.